Status:
COMPLETED
Long-term Effectiveness and Safety in Hepatitis-co-infected Patients
Lead Sponsor:
Abbott
Conditions:
Human Immunodeficiency Virus-Infection
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the study is to observe the tolerability and effectiveness of Kaletra in Human Immunodeficiency Virus/Hepatitis-B Virus and Human Immunodeficiency Virus/Hepatitis-C Virus co-infected patien...
Eligibility Criteria
Inclusion
- Patients infected by HIV-1 and HBV or HCV
- Age ≥18 years
- Patients who were initiated on a LPV/r containing antiretroviral (ARV) regimen
Exclusion
- \- Contraindications as described in SmPC (summary of product characteristics) at the time of prescription
Key Trial Info
Start Date :
May 1 2001
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
33 Patients enrolled
Trial Details
Trial ID
NCT01153269
Start Date
May 1 2001
End Date
November 1 2010
Last Update
December 19 2011
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Site Reference ID/Investigator# 27575
Berlin, Germany, 10243
2
Site Reference ID/Investigator# 27592
Berlin, Germany, 10961
3
Site Reference ID/Investigator# 27588
Dortmund, Germany, 44137
4
Site Reference ID/Investigator# 27583
Frankfurt, Germany, 60311